Srikripa Devarakonda
Stock Analyst at Truist Securities
(1.79)
# 3,017
Out of 4,829 analysts
64
Total ratings
27.87%
Success rate
-7.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Downgrades: Hold | $21 → $11 | $6.61 | +66.41% | 1 | May 5, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $975 → $940 | $527.78 | +78.10% | 7 | Apr 30, 2025 | |
| BIIB Biogen | Maintains: Buy | $210 → $199 | $118.17 | +68.40% | 4 | Apr 29, 2025 | |
| KROS Keros Therapeutics | Maintains: Buy | $43 → $25 | $13.65 | +83.15% | 5 | Apr 9, 2025 | |
| INCY Incyte | Maintains: Hold | $74 → $72 | $58.98 | +22.08% | 9 | Mar 18, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $60 → $76 | $42.95 | +76.95% | 2 | Mar 11, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,029 → $1,038 | $734.57 | +41.31% | 4 | Feb 3, 2025 | |
| ABBV AbbVie | Maintains: Buy | $211 → $217 | $184.60 | +17.55% | 3 | Feb 3, 2025 | |
| PFE Pfizer | Maintains: Buy | $36 → $32 | $22.28 | +43.63% | 1 | Dec 18, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Buy | $33 → $50 | $14.58 | +242.94% | 6 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $45 | $30.67 | +46.72% | 4 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $54 → $53 | $30.07 | +76.26% | 3 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $54 | $1.63 | +3,212.88% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $7.17 | +109.21% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $9.50 | +278.95% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $70 | $31.70 | +120.86% | 4 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $60 | $0.69 | +8,659.12% | 2 | Aug 11, 2023 |
Arvinas
May 5, 2025
Downgrades: Hold
Price Target: $21 → $11
Current: $6.61
Upside: +66.41%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Buy
Price Target: $975 → $940
Current: $527.78
Upside: +78.10%
Biogen
Apr 29, 2025
Maintains: Buy
Price Target: $210 → $199
Current: $118.17
Upside: +68.40%
Keros Therapeutics
Apr 9, 2025
Maintains: Buy
Price Target: $43 → $25
Current: $13.65
Upside: +83.15%
Incyte
Mar 18, 2025
Maintains: Hold
Price Target: $74 → $72
Current: $58.98
Upside: +22.08%
Protagonist Therapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $60 → $76
Current: $42.95
Upside: +76.95%
Eli Lilly and Company
Feb 3, 2025
Maintains: Buy
Price Target: $1,029 → $1,038
Current: $734.57
Upside: +41.31%
AbbVie
Feb 3, 2025
Maintains: Buy
Price Target: $211 → $217
Current: $184.60
Upside: +17.55%
Pfizer
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $22.28
Upside: +43.63%
Edgewise Therapeutics
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $14.58
Upside: +242.94%
Nov 25, 2024
Maintains: Buy
Price Target: $36 → $45
Current: $30.67
Upside: +46.72%
Nov 1, 2024
Reiterates: Buy
Price Target: $54 → $53
Current: $30.07
Upside: +76.26%
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $1.63
Upside: +3,212.88%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $7.17
Upside: +109.21%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $9.50
Upside: +278.95%
May 29, 2024
Maintains: Buy
Price Target: $86 → $70
Current: $31.70
Upside: +120.86%
Aug 11, 2023
Maintains: Buy
Price Target: $80 → $60
Current: $0.69
Upside: +8,659.12%